[15] Jak3 and Jak1 are activated following ligand ... transduction and are being considered as targets for inhibition in RA. GM-CSF, IL-3 and IL-5 signal through Jak2. Il-6, IL-10, IL-11, IL ...
In one of the cell lines and in 4 of 19 (21%) NKCL primary tumor samples, constitutive JAK3 activation was related to an acquired mutation (A573V or V722I) in the JAK3 pseudokinase domain.
Hosted on MSN1mon
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 InhibitorATI-2138 exhibits the ability to selectively and potently block interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3), playing a key role in modulating T cell activity involved in ...
The new publication demonstrates that ATI-2138 exhibits a unique mechanism of action as a dual inhibitor of ITK and JAK3, suggesting it may be a best-in-class treatment option. Results from ...
“ATI-2138 potently and selectively blocks both ITK and JAK3. Through this mechanism, ATI-2138 has been shown in preclinical studies to effectively inhibit Th1, Th2 and Th17 cell ...
“ATI-2138 potently and selectively blocks both ITK and JAK3. Through this mechanism, ATI-2138 has been shown in preclinical studies to effectively inhibit Th1, Th2 and Th17 cell activity, which are ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback